{
    "sid": 19307938,
    "pkdb_version": 1.0,
    "creator": "mkoenig",
    "name": "Ghassabian2009",
    "substances": [
        "caffeine"
    ],
    "reference": 19307938,
    "curators": [
        "mkoenig",
        "janekg"
    ],
    "groupset": {
        "description": "The assay was applied to samples collected in a pilot study of people with schizophrenia who were receiving Clozapine. Participants were selected on the basis of having no history of chronic diseases such as diabetes, asthma, and cancer, and women could not be pregnant at the time of study. 11 people with schizophrenia who were receiving\nclozapine provided informed consent, participated, and\nsuccessfully completed the pilot clinical study (Table 5).\nNone of the subjects experienced serious side effects after\nadministration of the drug cocktail.",
        "groups": [
            {
                "count": 11,
                "name": "S1",
                "characteristica": [
                    {
                        "category": "smoking",
                        "choice": null
                    },
                    {
                        "category": "species",
                        "choice": "homo sapiens"
                    },
                    {
                        "category": "disease",
                        "choice": "schizophrenia"
                    },
                    {
                        "category": "age",
                        "mean": "41.09",
                        "min": "22",
                        "max": "66",
                        "sd": "14.56",
                        "unit": "yr"
                    },
                    {
                        "category": "healthy",
                        "choice": "Y"
                    },
                    {
                        "category": "sex",
                        "choice": "9 M || 2 F"
                    }
                ]
            }
        ]
    },
    "individualset": {
        "description": "",
        "individuals": [
            {
                "data": "Ghassabian2009_Tab5.csv",
                "figure": "Ghassabian2009_Tab5.png"
            }
        ]
    },
    "interventionset": {
        "description": "After informed consent was obtained, subjects abstained from caffeine-containing products for 48 hours before and during the period of the study. Subjects were provided with caffeinefree beverages during this period. Each study participant received the combination of 100 mg caffeine, 20 mg omeprazole, 25 mg losartan, 30 mg dextromethorphan (as an oral liquid), and an oral dose of 2 mg midazolam (in 5% dextrose solution). Venous blood samples (10 mL) were collected before administration of the cocktail and at 1-, 2-, 4-, and 6-hour postadministration.",
        "interventions": [
            {
                "name": "D1",
                "substance": "caffeine",
                "time": "0",
                "time_unit": "h",
                "route": "oral",
                "value": 100.0,
                "unit": "mg"
            }
        ]
    },
    "outputset": {
        "description": "",
        "outputs": []
    }
}